Last €29.77 EUR
Change Today +0.05 / 0.17%
Volume 38.0K
DIA On Other Exchanges
Symbol
Exchange
BrsaItaliana
Stuttgart
OTC US
OTC US
As of 11:30 AM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

diasorin spa (DIA) Snapshot

Open
€29.72
Previous Close
€29.72
Day High
€29.93
Day Low
€29.50
52 Week High
01/6/14 - €39.22
52 Week Low
08/8/14 - €26.00
Market Cap
1.7B
Average Volume 10 Days
34.0K
EPS TTM
€1.51
Shares Outstanding
55.9M
EX-Date
05/19/14
P/E TM
19.7x
Dividend
€0.55
Dividend Yield
1.85%
Current Stock Chart for DIASORIN SPA (DIA)

Related News

No related news articles were found.

diasorin spa (DIA) Related Businessweek News

No Related Businessweek News Found

diasorin spa (DIA) Details

DiaSorin S.p.A. is engaged in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in different clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products for diagnosis of infectious diseases; immunoassays for the management of bone and calcium metabolic related diseases; endocrinology products for endocrine system diseases; such as diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology, bone and calcium metabolic related diseases, hypertension, and oncology; enzyme linked immunosorbent assays; and SPQ serum protein quantification assays. Its immunodiagnostics instruments include LIAISON XL, an automated chemiluminescence analyzer; LIAISON analyzer; ETI Max 3000, an automated microtiter plate analyzer; EVOlyzer 2-150/8 with disposable tips; and ELISA washers and readers. The company also offers molecular diagnostic products, including systems, software, kits, reagents, and consumables, such as Bullet Pro to perform extractions from different biological samples as required in big laboratories; LIAISON IXT to extract the nucleic acid from different biological samples and it is used in combination with LIAISON IAM amplification system; and LIAISON IAM to diagnose and monitor various infectious diseases and Onco-hematology parameters. In addition, it provides Middleware DiaLink 3000, a middleware solution. The company sells its products directly, as well as through an international network of independent distributors in Europe, Africa, Central America, South America, the Asia Pacific, and North America. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy.

Founded in 1968

diasorin spa (DIA) Top Compensated Officers

Chief Executive Officer, General Manager and ...
Total Annual Compensation: €705.5K
Senior Corporate Vice President of Commercial...
Total Annual Compensation: €435.7K
Compensation as of Fiscal Year 2013.

diasorin spa (DIA) Key Developments

DiaSorin Launches Sixth LIAISON Test for Adenovirus on Stool Sample

DiaSorin has launched its sixth LIAISON test for the qualitative detection of Adenovirus in stool samples, available in the market outside the US and UK only. The test is an addition to the 5 most important tests of the "stool testing" panel, already available on the market (C. Difficile toxin A&B, C. Difficile GDH, Helicobacter Pylori, EHEC, Rotavirus). Adenovirus - a virus that is resistant to drugs and dangerous for infants, children and immunosuppressed patients - is, along with Rotavirus, extremely spread-out worldwide and is the first gastro-intestinal infection in terms of volumes tested: in Europe alone, about 5.5 million tests are made every year for a market that is estimated at more than 9 million. Throughout the world, the Adenovirus test is usually done in conjunction with that for Rotavirus (combo test "Rota /Adeno").

DiaSorin S.p.A., H1 2014 Earnings Call, Aug 01, 2014

DiaSorin S.p.A., H1 2014 Earnings Call, Aug 01, 2014

DiaSorin S.p.A. Reports Consolidated Earnings Results for the Second Quarter and First Half Ended June 30, 2014

DiaSorin S.p.A. reported consolidated earnings results for the second quarter and first half ended June 30, 2014. For the quarter, the company reported sales and service revenues of EUR 110,856,000 against EUR 113,880,000 a year ago. EBIT was EUR 32,040,000 against EUR 35,401,000 a year ago. Profit before taxes was EUR 31,963,000 against EUR 33,584,000 a year ago. Net profit was EUR 20,271,000 against EUR 20,515,000 a year ago. EBITDA was EUR 39,490,000 against EUR 42,293,000 a year ago. For the first half, the company reported sales and service revenues of EUR 216,771,000 against EUR 219,719,000 a year ago. EBIT was EUR 63,388,000 against EUR 69,583,000 a year ago. Profit before taxes was EUR 62,852,000 against EUR 66,714,000 a year ago. Net profit was EUR 39,973,000 against EUR 41,041,000 a year ago. EBITDA was EUR 78,077,000 against EUR 83,873,000 a year ago. Net cash from operating activities was EUR 52,870,000 against EUR 48,744,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DIA:IM €29.77 EUR +0.05

DIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $114.26 USD +0.86
BioMerieux €83.55 EUR +1.58
Corgenix Medical Corp $0.25 USD +0.0009
ERBA Diagnostics Inc $3.56 USD +0.04
Meridian Bioscience Inc $17.67 USD -0.02
View Industry Companies
 

Industry Analysis

DIA

Industry Average

Valuation DIA Industry Range
Price/Earnings 18.2x
Price/Sales 3.5x
Price/Book 3.5x
Price/Cash Flow 18.7x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIASORIN SPA, please visit www.diasorin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.